Determination of serum mucin 1 (MUC-1) and carcinoembryonic antigen (CEA) levels for monitoring of breast cancer patients with metastatic disease during active therapy are the only two circulating biomarkers currently recommended by the American Society of Clinical Oncology (ASCO) as supplementary tests [6]. The gene discussed is CEACAM5; the disease is breast carcinoma.